Cargando…
Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione, with antitumor activity and a mechanism of action markedly different from other available agents. This phase 2, nonrandomized, single-arm, open-label study evaluated the efficacy and safety of intra...
Autores principales: | Kim, Won-Seog, Fukuhara, Noriko, Yoon, Dok-Hyun, Yamamoto, Kazuhito, Uchida, Toshiki, Negoro, Eiju, Izutsu, Koji, Terui, Yasuhito, Nakajima, Hideaki, Ando, Kiyoshi, Suehiro, Youko, Kang, Hye Jin, Ko, Po-Shen, Nagahama, Fumiko, Sonehara, Yusuke, Nagai, Hirokazu, Tien, Hwei-Fang, Kwong, Yok-Lam, Tobinai, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463191/ https://www.ncbi.nlm.nih.gov/pubmed/36661315 http://dx.doi.org/10.1182/bloodadvances.2022008615 |
Ejemplares similares
-
Japanese subgroup analysis in the Asian phase II study of darinaparsin in
patients with relapsed or refractory peripheral T-cell lymphoma
por: Negoro, Eiju, et al.
Publicado: (2023) -
Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea
por: Ogura, Michinori, et al.
Publicado: (2020) -
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2020) -
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient
por: Nielsen, Torsten H., et al.
Publicado: (2013) -
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)